AMICUS THERAPEUTICS UK OPERATIONS LIMITED
Get an alert when AMICUS THERAPEUTICS UK OPERATIONS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-08-22 (in 3mo)
Last made up 2025-08-08
Watchouts
None on the register
Cash
£7M
+16.6% vs 2023
Net assets
£6M
+45.7% vs 2023
Employees
13
0% vs 2023
Profit before tax
£2M
+56.3% vs 2023
Profit before tax
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £33,200,924 | £51,960,671 | |
| Operating profit | £996,029 | £1,556,497 | |
| Profit before tax | £996,029 | £1,556,497 | |
| Net profit | £996,029 | £1,556,497 | |
| Cash | £5,924,943 | £6,908,462 | |
| Total assets less current liabilities | £4,368,923 | £6,366,120 | |
| Net assets | — | — | |
| Equity | £4,368,923 | £6,366,120 | |
| Average employees | 13 | 13 | |
| Wages | £1,369,059 | £1,408,768 | |
| Directors' remuneration | £43,018 | £111,632 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+56.5%
£33,200,924 £51,960,671
-
Cash
+16.6%
£5,924,943 £6,908,462
-
Net assets
—
Not reported
-
Employees
0%
13 13
-
Operating profit
+56.3%
£996,029 £1,556,497
-
Profit before tax
+56.3%
£996,029 £1,556,497
-
Wages
+2.9%
£1,369,059 £1,408,768
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 3.0% | 3.0% | |
| Net margin | 3.0% | 3.0% | |
| Return on capital employed | 22.8% | 24.4% | |
| Current ratio | 1.23x | 1.31x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company is dependent upon its ultimate parent company, Amicus Therapeutics Inc., for both product supply and access to cash resources. In view of this, the directors have received written confirmation from Amicus Therapeutics Inc. that they will make funds available to the Company to enable it to meet its liabilities as they fall due for a period of at least 12 months from the date of approval of these financial statements.”
Significant events
- “In August 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (U.K.) has granted marketing authorizations for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) for adults living with late-onset Pompe disease. Pombiliti + Opfolda was launched in September 2023.”
- “In October 2023, Amicus Therapeutics Inc. entered into a loan agreement with Blackstone for $400m in order to repay existing group debt and provide adequate working capital for the future. Amicus Therapeutics Ltd. provided a first lien security interest over cash held in its bank account and its trade debtor balances.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CLARK, Laura Ruth | Director | 2024-09-27 | Oct 1982 | British |
| GALVIN, Charlotte Ann | Director | 2019-08-09 | Mar 1978 | British |
| GREEN, Steven John | Director | 2020-06-01 | Apr 1977 | British |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| COLLINS, Simon Timothy Martin | Director | 2019-08-09 | 2024-07-26 |
| LEWIS, David Malcolm | Director | 2024-02-12 | 2024-07-26 |
| MOCHAN, Lori Elizabeth | Director | 2019-08-09 | 2020-02-21 |
| REICHMAN, Nicole Ruth | Director | 2019-08-09 | 2021-04-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Amicus Therapeutics Uk Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-08-09 | Active |
Filing timeline
Last 20 of 25 total filings
Material constitutional events — rename, articles re-file, resolution
- 2020-08-11 MA Memorandum articles
- 2020-08-11 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-08-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-04-07 | AA | accounts | Accounts with accounts type full | |
| 2024-10-01 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-05 | AA | accounts | Accounts with accounts type full | |
| 2024-08-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-08-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-26 | TM01 | officers | Termination director company with name termination date | |
| 2024-02-13 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-13 | AA | accounts | Accounts with accounts type full | |
| 2023-10-12 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-10-09 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2023-08-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-09-29 | AA | accounts | Accounts with accounts type full | |
| 2022-08-10 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-08-23 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-06-28 | AA | accounts | Accounts with accounts type full | |
| 2021-04-06 | TM01 | officers | Termination director company with name termination date | |
| 2020-08-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2020-08-11 | MA | incorporation | Memorandum articles | |
| 2020-08-11 | RESOLUTIONS | resolution | Resolution |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 1
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.